多发性骨髓瘤与骨病：发病机制及当前治疗方法
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.
作者信息
Papadopoulou E C, Batzios S P, Dimitriadou M, Perifanis V, Garipidou V
机构信息
Haematology Section, 2 Propedeutic, Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokratio General Hospital, Thessaloniki, Greece.
出版信息
Hippokratia. 2010 Apr;14(2):76-81.
Abstract
Multiple myeloma is a haematologic malignancy caused by clonal expansion of malignant plasma cells and associated with bone disease and hypercalcaemia. Myeloma cells are in close proximity to sites of active bone resorption and the interactions between those cells, osteoblasts and osteoclasts, are crucial not only for the bone distraction but for the proliferation of bone marrow cells as well. Recent studies have revealed that numerous regulating factors of osteoblast and osteoclast activity interfere with the pathogenesis of multiple myeloma's bone disease and that the understanding of the pathophysiological pathways involved is the first step towards discovering novel potential therapeutic approaches.
摘要
多发性骨髓瘤是一种血液系统恶性肿瘤，由恶性浆细胞的克隆性增殖引起，与骨病和高钙血症相关。骨髓瘤细胞与活跃的骨吸收部位紧密相邻，这些细胞、成骨细胞和破骨细胞之间的相互作用不仅对骨破坏至关重要，对骨髓细胞的增殖也很关键。最近的研究表明，许多成骨细胞和破骨细胞活性的调节因子会干扰多发性骨髓瘤骨病的发病机制，而了解其中涉及的病理生理途径是发现新的潜在治疗方法的第一步。
相似文献
1
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.
Hippokratia. 2010 Apr;14(2):76-81.
2
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Dan Med Bull. 2011 May;58(5):B4277.
3
The pathogenesis of the bone disease of multiple myeloma.
Bone. 2008 Jun;42(6):1007-13. doi: 10.1016/j.bone.2008.01.027. Epub 2008 Feb 21.
4
Myeloma bone disease: Progress in pathogenesis.
Prog Biophys Mol Biol. 2016 Nov;122(2):149-155. doi: 10.1016/j.pbiomolbio.2016.08.003. Epub 2016 Aug 3.
5
Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Cancer Res. 2005 Nov 1;65(21):9943-52. doi: 10.1158/0008-5472.CAN-05-0651.
6
An Evidence-Based Approach to Myeloma Bone Disease.
Curr Hematol Malig Rep. 2017 Apr;12(2):109-118. doi: 10.1007/s11899-017-0370-5.
7
Myeloma bone disease: pathogenesis, current treatments and future targets.
Br Med Bull. 2014 Sep;111(1):117-38. doi: 10.1093/bmb/ldu016.
8
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Exp Cell Res. 2008 Mar 10;314(5):1082-93. doi: 10.1016/j.yexcr.2007.10.021. Epub 2007 Nov 7.
9
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.
Bone. 2015 Jun;75:161-9. doi: 10.1016/j.bone.2015.02.021. Epub 2015 Feb 26.
10
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Int J Mol Sci. 2021 Apr 24;22(9):4462. doi: 10.3390/ijms22094462.
引用本文的文献
1
Advances in Supportive Care for Multiple Myeloma-Related Bone Disease-A Review.
Cancers (Basel). 2025 Jun 27;17(13):2166. doi: 10.3390/cancers17132166.
2
Multiple Myeloma: A Review of the Literature and a Case Report Highlighting the Immunocompromised State of Myeloma Patients.
World J Oncol. 2024 Jun;15(3):348-354. doi: 10.14740/wjon1780. Epub 2024 Apr 15.
3
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.
Int J Mol Sci. 2020 Jul 15;21(14):5002. doi: 10.3390/ijms21145002.
4
Clinical significance of trabecular bone score for prediction of pathologic fracture risk in patients with multiple myeloma.
Osteoporos Sarcopenia. 2018 Jun;4(2):73-76. doi: 10.1016/j.afos.2018.05.003. Epub 2018 Jun 11.
5
I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.
Biosci Rep. 2019 May 14;39(5). doi: 10.1042/BSR20181245. Print 2019 May 31.
6
New agents in the Treatment of Myeloma Bone Disease.
Calcif Tissue Int. 2018 Feb;102(2):196-209. doi: 10.1007/s00223-017-0351-7. Epub 2017 Nov 2.
7
Effect of The Receptor Activator of Nuclear Factor кB and RANK Ligand on In Vitro Differentiation of Cord Blood CD133(+) Hematopoietic Stem Cells to Osteoclasts.
Cell J. 2016 Fall;18(3):322-31. doi: 10.22074/cellj.2016.4559. Epub 2016 Aug 24.
8
Bone disease in multiple myeloma: pathophysiology and management.
Cancer Growth Metastasis. 2014 Aug 10;7:33-42. doi: 10.4137/CGM.S16817. eCollection 2014.
9
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
PLoS One. 2014 Apr 10;9(4):e94395. doi: 10.1371/journal.pone.0094395. eCollection 2014.
10
Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.
Semin Hematol. 2011 Jan;48(1):55-65. doi: 10.1053/j.seminhematol.2010.11.001.
本文引用的文献
1
Targeting proteasomes as therapy in multiple myeloma.
Adv Exp Med Biol. 2008;615:251-60. doi: 10.1007/978-1-4020-6554-5_12.
2
The pathogenesis of the bone disease of multiple myeloma.
Bone. 2008 Jun;42(6):1007-13. doi: 10.1016/j.bone.2008.01.027. Epub 2008 Feb 21.
3
Denosumab: RANKL inhibition in the management of bone loss.
Drugs Today (Barc). 2008 Jan;44(1):7-21. doi: 10.1358/dot.2008.44.1.1178467.
4
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
Br J Haematol. 2007 Nov;139(3):434-8. doi: 10.1111/j.1365-2141.2007.06829.x.
5
Clinical development of anti-RANKL therapy.
Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S7. doi: 10.1186/ar2171.
6
Multiple myeloma/hypercalcemia.
Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S4. doi: 10.1186/ar2168.
7
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Leukemia. 2007 Sep;21(9):1875-84. doi: 10.1038/sj.leu.2404843. Epub 2007 Jul 5.
8
New drugs for myeloma.
Oncologist. 2007 Jun;12(6):664-89. doi: 10.1634/theoncologist.12-6-664.
9
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Blood. 2007 Jul 1;110(1):334-8. doi: 10.1182/blood-2006-11-059188. Epub 2007 Mar 19.
10
Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Clin Cancer Res. 2007 Feb 1;13(3):816-23. doi: 10.1158/1078-0432.CCR-06-2258.
Zotero 插件